As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - diversified industry, including CooperCompanies (NASDAQ: COO) and its peers.
The medical devices industry operates a business model that balances steady demand with significant investments in innovation and regulatory compliance. The industry benefits from recurring revenue streams tied to consumables, maintenance services, and incremental upgrades to the latest technologies. However, the capital-intensive nature of product development, coupled with lengthy regulatory pathways and the need for clinical validation, can weigh on profitability and timelines. In addition, there are constant pricing pressures from healthcare systems and insurers maximizing cost efficiency. Over the next several years, one tailwind is demographic–aging populations means rising chronic disease rates that drive greater demand for medical interventions and monitoring solutions. Advances in digital health, such as remote patient monitoring and smart devices, are also expected to unlock new demand by shortening upgrade cycles. On the other hand, the industry faces headwinds from pricing and reimbursement pressures as healthcare providers increasingly adopt value-based care models. Additionally, the integration of cybersecurity for connected devices adds further risk and complexity for device manufacturers.
The 5 medical devices & supplies - diversified stocks we track reported a strong Q1. As a group, revenues beat analysts’ consensus estimates by 2.9% while next quarter’s revenue guidance was 2.2% below.
Thankfully, share prices of the companies have been resilient as they are up 5.3% on average since the latest earnings results.
CooperCompanies (NASDAQ: COO)
With a history dating back to 1958 and a portfolio spanning two distinct healthcare segments, Cooper Companies (NASDAQ: COO) develops and manufactures medical devices focused on vision care through contact lenses and women's health including fertility products and services.
CooperCompanies reported revenues of $1.08 billion, up 7.9% year on year. This print exceeded analysts’ expectations by 2.7%. Overall, it was a strong quarter for the company with a solid beat of analysts’ organic revenue estimates and a beat of analysts’ EPS estimates.
CooperCompanies delivered the weakest full-year guidance update in the group. Interestingly, the stock is up 9% since reporting and currently trades at $67.62.
Is now the time to buy CooperCompanies? Access our full analysis of the earnings results here, it’s free.
Best Q1: Baxter (NYSE: BAX)
With a history dating back to 1931 and products used in over 100 countries, Baxter International (NYSE: BAX) provides essential healthcare products including dialysis therapies, IV solutions, infusion systems, surgical products, and patient monitoring technologies to hospitals and clinics worldwide.
Baxter reported revenues of $2.96 billion, up 5.3% year on year, outperforming analysts’ expectations by 6%. The business had an incredible quarter with a beat of analysts’ EPS estimates and an impressive beat of analysts’ full-year EPS guidance estimates.
However, the results were likely priced into the stock as it’s traded sideways since reporting. Shares currently sit at $24.95.
Is now the time to buy Baxter? Access our full analysis of the earnings results here, it’s free.
Weakest Q1: Boston Scientific (NYSE: BSX)
Founded in 1979 with a mission to advance less-invasive medicine, Boston Scientific (NYSE: BSX) develops and manufactures medical devices used in minimally invasive procedures across cardiovascular, urological, neurological, and gastrointestinal specialties.
Boston Scientific reported revenues of $5.44 billion, up 7.5% year on year, exceeding analysts’ expectations by 1.5%. Still, it was a softer quarter as it posted revenue guidance for next quarter missing analysts’ expectations significantly and a miss of analysts’ full-year EPS guidance estimates.
As expected, the stock is down 2.1% since the results and currently trades at $45.08.
Read our full analysis of Boston Scientific’s results here.
Stryker (NYSE: SYK)
With over 150 million patients impacted annually through its innovative healthcare technologies, Stryker (NYSE: SYK) develops and manufactures advanced medical devices and equipment across orthopedics, surgical tools, neurotechnology, and patient care solutions.
Stryker reported revenues of $6.59 billion, up 9.4% year on year. This print met analysts’ expectations. More broadly, it was a mixed quarter as it also produced a beat of analysts’ EPS estimates but organic revenue in line with analysts’ estimates.
Stryker had the weakest performance against analyst estimates of the whole group. The stock is down 20.2% since reporting and currently trades at $277.82.
Read our full, actionable report on Stryker here, it’s free.
Abbott Laboratories (NYSE: ABT)
With roots dating back to 1888 when founder Dr. Wallace Abbott began producing precise, dosage-form medications, Abbott Laboratories (NYSE: ABT) develops and sells a diverse range of healthcare products including medical devices, diagnostics, nutrition products, and branded generic pharmaceuticals.
Abbott Laboratories reported revenues of $12.59 billion, up 13% year on year. This number surpassed analysts’ expectations by 1.1%. Overall, it was a satisfactory quarter as it also put up a narrow beat of analysts’ full-year EPS guidance estimates.
Abbott Laboratories pulled off the fastest revenue growth among its peers. The stock is up 18.3% since reporting and currently trades at $105.65.
Read our full, actionable report on Abbott Laboratories here, it’s free.
Market Update
Over the past year, investors have been forced to repeatedly answer the same question: what is the market’s biggest risk? The answer has changed several times, and each shift has reshaped market leadership.
Late in 2025 and early 2026, artificial intelligence became the market’s primary uncertainty. Investors questioned whether AI would erode software pricing power and weaken competitive moats as AI made it easier to replicate once-differentiated products.
By the spring, technology took a back seat to geopolitics. The U.S. conflict with Iran briefly became the market’s dominant narrative, raising concerns about oil prices, inflation, and global growth. But as energy markets remained orderly and fears of a prolonged supply disruption faded, investors quickly turned their focus back to fundamentals.
Want to invest in winners with rock-solid fundamentals? Check out our Top 6 Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.
